行情

HTBX

HTBX

Heat Biologics
NASDAQ

实时行情|Nasdaq Last Sale

0.5300
+0.0950
+21.84%
盘前: 0.5700 +0.04 +7.55% 08:17 11/20 EST
开盘
0.4600
昨收
0.4350
最高
0.5800
最低
0.4400
成交量
359.73万
成交额
--
52周最高
2.100
52周最低
0.3500
市值
1,809.45万
市盈率(TTM)
-0.8062
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

HTBX 新闻

  • 拼多多Q3净亏损超预期 盘前跌逾20%市值回落百度之后
  • 新浪财经.2小时前
  • 拼多多三季度营收低于市场预期 盘前大跌13%
  • 新浪科技.2小时前
  • 定价176港元,阿里巴巴首日盈利空间还有多大?
  • 华盛通.2小时前
  • 阿里巴巴融资880亿港元 为2010年以来香港最大IPO
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
+1.97%
制药与医学研究
+0.74%

热门股票

名称
价格
涨跌幅

HTBX 简况

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
展开

Webull提供Heat Biologics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。